TS-143 clinical trials
Also written TS-143.
- studies test it
- 3
- open now
- 0
- in phase 3
- 0
- first study started
- 2015
How each study uses TS-143 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Development codes
- TS-143
- 3
Studies by the year they started
3 studies that test it; most in 2015 (1)
| Year | Studies |
|---|---|
| 2015 | 1 |
| 2016 | 1 |
| 2017 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 3
Who runs them
Industry 3 · Other 0
Studies
Open first, then newest update. How each study uses TS-143 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 3
- Clinical Study of TS-143 in Healthy Adult Male Subjects (Multiple-Dose Administration)CompletedPhase 1Taisho Pharmaceutical Co., Ltd.NCT03595202Written as TS-143How we know
- Clinical Pharmacology Study of TS-143 in Nondialysis and Hemodialysis Patients with Chronic Kidney DiseaseCompletedPhase 1Taisho Pharmaceutical Co., Ltd.NCT03581071Written as TS-143How we know
- Clinical Study of TS-143 in Healthy Adult Male Subjects (Single-Dose Administration)CompletedPhase 1Taisho Pharmaceutical Co., Ltd.NCT03591133Written as TS-143How we know